ImmuPharma PLC (IMM) — Working Capital to Net Assets Ratio
ImmuPharma PLC (IMM) has a Working Capital to Net Assets ratio of 76.5% as of June 2025. Working capital of GBX257.41K (current assets of GBX1.50 Million minus current liabilities of GBX1.24 Million) is measured against net assets of GBX336.70K. A higher ratio indicates strong short-term liquidity financed by the equity base. See IMM defensive interval ratio to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
ImmuPharma PLC Working Capital to Net Assets (2004–2024)
This chart shows how ImmuPharma PLC's Working Capital to Net Assets ratio has evolved across 22 annual periods from 2004 to 2024. As of June 2025, the ratio stands at 76.5%, reflecting working capital of GBX257.41K against net assets of GBX336.70K GBX. For the complete balance sheet picture, see ImmuPharma PLC asset portfolio.
Annual Working Capital to Net Assets for ImmuPharma PLC (2004–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for ImmuPharma PLC from 2004 to 2024, covering 22 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check how resilient are ImmuPharma PLC's assets to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (GBX) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 117.0% | GBX-635.00K | GBX-542.86K | GBX884.87K | GBX1.52 Million | ▲ +147.5 pp |
| 2023 | -30.5% | GBX-321.92K | GBX1.06 Million | GBX1.34 Million | GBX1.67 Million | ▼ -65.7 pp |
| 2022 | 35.2% | GBX887.63K | GBX2.52 Million | GBX2.34 Million | GBX1.45 Million | ▼ -4.7 pp |
| 2021 | 39.9% | GBX1.76 Million | GBX4.41 Million | GBX3.35 Million | GBX1.58 Million | ▼ -24.0 pp |
| 2020 | 63.9% | GBX6.17 Million | GBX9.65 Million | GBX7.43 Million | GBX1.26 Million | ▲ +6.0 pp |
| 2019 | 57.9% | GBX3.05 Million | GBX5.27 Million | GBX3.58 Million | GBX531.87K | ▼ -7.7 pp |
| 2018 | 65.6% | GBX5.00 Million | GBX7.62 Million | GBX6.01 Million | GBX1.01 Million | ▼ -25.2 pp |
| 2017 | 90.8% | GBX3.24 Million | GBX3.57 Million | GBX4.37 Million | GBX1.13 Million | ▲ +0.2 pp |
| 2016 | 90.6% | GBX5.02 Million | GBX5.55 Million | GBX5.97 Million | GBX944.35K | ▲ +21.4 pp |
| 2015 | 69.1% | GBX1.17 Million | GBX1.69 Million | GBX2.41 Million | GBX1.24 Million | ▼ -21.2 pp |
| 2014 | 90.3% | GBX5.15 Million | GBX5.71 Million | GBX6.15 Million | GBX990.97K | ▼ -11.0 pp |
| 2013 | 101.3% | GBX5.47 Million | GBX5.40 Million | GBX6.51 Million | GBX1.03 Million | ▼ -2.2 pp |
| 2012 | 103.5% | GBX8.71 Million | GBX8.42 Million | GBX9.77 Million | GBX1.05 Million | ▲ +3.2 pp |
| 2011 | 100.3% | GBX12.54 Million | GBX12.51 Million | GBX13.49 Million | GBX946.00K | ▲ +0.4 pp |
| 2010 | 99.9% | GBX15.96 Million | GBX15.97 Million | GBX16.77 Million | GBX811.00K | ▲ +1.8 pp |
| 2009 | 98.2% | GBX17.75 Million | GBX18.08 Million | GBX23.89 Million | GBX6.13 Million | ▼ -1.4 pp |
| 2008 | 99.6% | GBX11.19 Million | GBX11.24 Million | GBX12.58 Million | GBX1.39 Million | ▲ +13.4 pp |
| 2007 | 86.2% | GBX2.63 Million | GBX3.05 Million | GBX3.33 Million | GBX704.00K | ▼ -7.8 pp |
| 2006 | 93.9% | GBX5.53 Million | GBX5.89 Million | GBX6.56 Million | GBX1.03 Million | ▲ +25.0 pp |
| 2006 | 69.0% | GBX1.73 Million | GBX2.50 Million | GBX2.85 Million | GBX1.12 Million | ▼ -31.0 pp |
| 2005 | 100.0% | GBX993.00K | GBX993.00K | GBX1.01 Million | GBX14.00K | ▲ +0.0 pp |
| 2004 | 100.0% | GBX978.00K | GBX978.00K | GBX980.00K | GBX2.00K | — |